MOTIVATION LETTER Addiction is a disorder of memory. The brain encodes a link between a drug and a reward, and that link persists for years, driving relapse even after detoxification. No existing pharmacotherapy prevents this encoding. The Conjunctive Consolidation Threshold model, which I developed as an independent researcher in Lagos, proposes a tripartite mechanism to block reward-memory consolidation at the moment of learning. My three sole-authored preprints on OSF and Zenodo specify the model, its formal mathematics, and a Bayesian clinical trial architecture. ODE/RK45 and Bayesian MCMC validation shows encoding probability drops from 0.855 to 0.122, an 85.8 percent reduction, with super-additivity of 12.8 percentage points. All five pre-registered hypotheses were confirmed. Emergent Ventures funds bold, unconventional ideas that challenge established approaches. The CCT model is precisely that. It is a high-risk, high-reward moonshot in addiction neuroscience, a field where the standard pipeline has produced no fundamentally new mechanism in decades. I am not a tenured professor or a PhD candidate. I am a 29-year-old Nigerian pharmacist who built the model, the mathematical proofs, the simulation code, and three open-source platforms IMPRINT, TOPOLOGIX, and GATE entirely outside a university lab. I filed a provisional patent on the core architecture in Q3 2026. I secured endorsements from Kent Berridge at Michigan, Samuel Gershman at Harvard, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU. These signals of credibility matter because the idea is radical. The societal cost of addiction is measured in trillions of dollars globally, and in lost lives, broken families, and overwhelmed health systems in Nigeria and across Africa. A therapy that prevents reward-memory encoding would change the standard of care. It would shift treatment from managing withdrawal and craving to preventing the disease from taking hold. That is the scale of impact Emergent Ventures seeks. I am applying for this grant to fund the next phase: a small-animal proof-of-concept study using the Bayesian trial architecture I have already designed, and to support my transition into a formal PhD programme at the Medical University of Graz starting October 2026. The grant would cover computational resources, open-access publication fees, and travel for collaboration with my endorsers. I do not have institutional overhead. Every dollar goes directly to the research. RESEARCH STATEMENT The Conjunctive Consolidation Threshold model addresses a fundamental gap in addiction neuroscience. Current pharmacotherapies for substance use disorders target either the acute rewarding effects of a drug or the withdrawal symptoms that follow abstinence. None target the memory consolidation process that binds drug-associated cues to reward value. This consolidation occurs within a critical window after each drug exposure. If it can be prevented, the drug never becomes a learned reward. The CCT model specifies three conjunctive conditions that must be met simultaneously for reward-memory encoding to occur: a minimum dopamine transient in the nucleus accumbens, a minimum glutamate signal from the prefrontal cortex to the ventral tegmental area, and a minimum norepinephrine-mediated arousal signal from the locus coeruleus. If any one of these three signals falls below its threshold during the consolidation window, the memory trace is not stabilized. The model predicts that a triple combination of sub-threshold pharmacological agents, each targeting one of these pathways, will produce super-additive blockade. My simulations confirm this: the combination reduces encoding probability by 85.8 percent, which is 12.8 percentage points greater than the sum of individual effects. The formal mathematical specification, available on OSF, models the system as a set of coupled ordinary differential equations solved with an RK45 integrator. The Bayesian population dynamics paper on Zenodo uses PyMC for Markov chain Monte Carlo estimation of the posterior distribution of encoding probabilities under different dosing regimens. The clinical trial architecture proposes a sequential, adaptive design with interim analyses at 25, 50, and 75 percent enrollment, using the posterior probability of super-additivity as the stopping criterion. My next step is a small-animal proof-of-concept study. I have designed the protocol using the Bayesian architecture. The primary endpoint is the proportion of animals that develop conditioned place preference for a sub-threshold dose of cocaine after pre-treatment with the triple combination. The study requires 40 animals across four groups, with a planned sample size that yields 90 percent power to detect a 50 percent reduction in CPP acquisition. I have identified a collaborator at a Nigerian university who can host the behavioral work. The grant would fund animal purchase, housing, drug costs, and data analysis. This work is independent. I have no supervisor, no lab, no institutional budget. I have a provisional patent, three preprints, three open-source platforms, and endorsements from four leading computational and affective neuroscientists. The CCT model is ready for empirical testing. Emergent Ventures funding would make that test possible. SHORT ESSAY: WHY THIS APPROACH IS BOLD AND UNDERFUNDED Addiction research funding follows established paradigms. The National Institute on Drug Abuse in the United States spends approximately one billion dollars annually, with the vast majority going to labs studying dopamine receptor pharmacology, optogenetic circuit mapping, and clinical trials of existing compounds. These approaches have not produced a fundamentally new mechanism of action in over twenty years. The CCT model proposes a mechanism that does not target the drug itself, but the memory of the drug. That is a paradigm shift. The model is underfunded because it does not fit neatly into any existing grant mechanism. It is not a standard R01 project. It is not a clinical trial of an approved compound. It is a theoretical model with a mathematical proof, a Bayesian trial design, and no preliminary animal data. Most funding agencies require preliminary data. I have simulation data, which is not considered preliminary by traditional reviewers. Emergent Ventures is one of the few programmes that funds ideas at this stage. The boldness is in the claim. I am asserting that addiction can be prevented by blocking memory consolidation, not by blocking the drug's acute effect. If the model is correct, it changes the entire treatment paradigm. If it is wrong, the simulations and the mathematics are still a contribution to the theoretical understanding of reward-memory encoding. Either outcome advances the field. SHORT ESSAY: MY INDEPENDENT RESEARCH PATH I completed my B.Pharm at the University of Ibadan in 2021 with a CGPA of 5.1 out of 7.0, equivalent to a German 1.9. I worked as a clinical pharmacist and as a research assistant in computational docking and antimicrobial resistance genomics. I did not enter a PhD programme immediately because I had an idea that did not fit any existing lab's focus. I chose to develop it independently. Between 2025 and 2026, I wrote three sole-authored preprints, built three computational platforms, filed a provisional patent, and secured endorsements from four senior neuroscientists. I did this while working full-time as a national product manager at Synthcare. I used open-source tools, free cloud computing credits, and the Python scientific stack. I learned TDA, persistent homology, and Bayesian MCMC on my own. I published on OSF and Zenodo because those platforms accept preprints without institutional affiliation. This path has been difficult. I have no mentor who reads my drafts. I have no lab meetings. I have no institutional email for grant applications. But it has also been liberating. I chose the problem, the method, and the timeline. I own the intellectual property. I am not waiting for a supervisor to approve my next experiment. I am ready to test the model now. CHECKLIST - [ ] Motivation letter, 300-500 words, tailored to Emergent Ventures mission - [ ] Research statement, 400-600 words, describing CCT model and next steps - [ ] Short essay on boldness and underfunding, 200-350 words - [ ] Short essay on independent research path, 200-350 words - [ ] CV or resume, formatted for Emergent Ventures submission portal - [ ] Links to three preprints on OSF and Zenodo - [ ] Links to IMPRINT, TOPOLOGIX, and GATE repositories on GitHub - [ ] Provisional patent filing number and date - [ ] Endorsement letters or emails from Kent Berridge, Samuel Gershman, Nathaniel Daw, and Marcelo Mattar - [ ] Proof of PCN pharmacist license - [ ] ORCID iD and GitHub profile URL - [ ] Budget outline for small-animal proof-of-concept study EDITOR NOTES - Eligibility risk: Emergent Ventures typically funds individuals and projects, not formal research studies with animal subjects. Confirm whether the grant can fund animal work or if it is restricted to computational and human-subject research. If restricted, reframe the budget as computational resources and open-access fees only. - Fact verification: Confirm the provisional patent was filed in Q3 2026 as stated. If not yet filed, remove the claim or specify "filing planned Q3 2026." - Gap: The profile does not specify which Nigerian university collaborator will host the animal study. Eniola must insert the collaborator's name, institution, and a brief confirmation of their willingness to host the work. - Gap: The profile does not specify the exact amount requested. Emergent Ventures grants vary. Eniola should determine a specific figure between 10,000 and 100,000 USD and include it in the motivation letter or budget outline. - Tone check: The short essays are within the 200-350 word range. Confirm the submission portal does not impose a stricter limit. If it does, trim accordingly.